Nezam Ibrahim Altorok

Nezam Altorok practices at University of Toledo Physicians in Toledo, Ohio.

Nezam Altorok's NPI, 1154585115, was assigned on July 17, 2008. Nezam Altorok holds Ohio license 35121127.

Nezam Altorok's primary practice is University of Toledo Physicians, at 4510 Dorr St, Toledo, OH 43615 in Lucas County. The practice phone is (419) 383-5000.

Nezam Altorok's primary practice is University of Toledo Physicians in Toledo, Ohio. Nezam Altorok is also affiliated with ProMedica Toledo Hospital. The medical group on file is UT Physicians Group. Dmand AI also links Nezam Altorok to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Nezam Altorok practices, 6 sites in all. Vendor and product names are available with a free account.

Rheumatology is Nezam Altorok's primary specialty in the NPI Registry, under taxonomy code 207RR0500X. Nezam Altorok is licensed in Ohio.

CMS data shows 3,018 Medicare services from Nezam Altorok across 12 procedure codes in 2024, for 345 Medicare patients. Medicare paid $82,130 for them.

CMS counts 345 Medicare patients who saw Nezam Altorok in 2024. The largest group is 65 to 74, with 153 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.08, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Nezam Altorok's median patient age at 68, with 68% women.

In 2024, Nezam Altorok wrote 3,741 Medicare Part D claims for 473 patients. 84% of them were for generic drugs. CMS names the drug for 3,428 of them, across 61 drugs with 11 or more claims each, at $3,234,379 in total drug cost. In 2023, CMS named 3,160 claims across 55 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Nezam Altorok for performance year 2024, reported as part of a group. Nezam Altorok accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Nezam Altorok as offering telehealth.

Dmand AI links 50 papers to Nezam Altorok, published from 2013 to 2024. 2022 was the busiest year, with 10. The most frequent topics are DNA Methylation, Methylprednisolone and Antibodies, Monoclonal, Humanized. Nezam Altorok has published most often in Am J Ther. Nezam Altorok's most frequent co-authors are Ragheb A. Assaly, MD, Waleed Shaheen Khokher, MD and Hazem Ayesh, MD.

Dmand AI links Nezam Altorok to 1 clinical trial. Conditions studied include Lupus Erythematosus, Systemic and Connective Tissue Diseases.

CMS Open Payments shows 567 general payments to Nezam Altorok from 29 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 69% of the total. UCB, Inc. paid the most, $2,775.